{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T14:07:34Z","timestamp":1776694054134,"version":"3.51.2"},"reference-count":16,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cedirogant is an inverse agonist of retinoic acid\u2010related orphan receptor gamma, thymus (ROR\u03b3t) developed for treatment of psoriasis. This study aimed to characterize pharmacokinetics, pharmacodynamics, safety, and tolerability of cedirogant following a single oral dose in Japanese participants and multiple oral doses in Japanese and Chinese participants. The single doses evaluated in healthy Japanese participants were 75, 225, and 395\u00a0mg. The multiple doses evaluated in both healthy Japanese and Chinese participants was 375\u00a0mg once daily for 14 days. Cedirogant plasma exposure increased dose proportionally with administration of single doses. Maximum cedirogant plasma concentration was reached within a median time of 4\u20105 hours after dosing. The harmonic mean elimination half\u2010life ranged from 19 to 25 hours. Cedirogant pharmacokinetics were similar between Japanese and Chinese participants. Compared with healthy Western participants in a cross\u2010study analysis, steady\u2010state cedirogant plasma exposure was 38%\u201073% higher in Japanese or Chinese participants. Ex vivo interleukin\u201017 inhibition increased in a dose\u2010dependent manner and was maximized by 375\u00a0mg once\u2010daily doses. The cedirogant regimens tested were generally well tolerated, and no new safety issues were identified. The results supported enrollment of Japanese and Chinese subjects in subsequent clinical trials for cedirogant.<\/jats:p>","DOI":"10.1002\/cpdd.1386","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T09:03:51Z","timestamp":1709024631000},"page":"801-809","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacokinetics, Safety, and Tolerability of Cedirogant in Healthy Japanese and Chinese Adults"],"prefix":"10.1002","volume":"13","author":[{"given":"Mohamed\u2010Eslam F","family":"Mohamed","sequence":"first","affiliation":[{"name":"Clinical Pharmacology AbbVie  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuli","family":"Qian","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronilda","family":"D'Cunha","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuai","family":"Hao","sequence":"additional","affiliation":[{"name":"Discovery and Exploratory Statistics AbbVie  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Carcereri De Prati","sequence":"additional","affiliation":[{"name":"Immunology Development AbbVie  Ludwigshafen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gweneth F","family":"Levy","sequence":"additional","affiliation":[{"name":"Pharmacovigilance and Patient Safety AbbVie  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinjal","family":"Hew","sequence":"additional","affiliation":[{"name":"Precision Medicine Immunology AbbVie  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology AbbVie  North Chicago IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2011.12.011"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2008.03040.x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2021.1948833"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3707"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.07.035"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2007.11.016"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004"},{"key":"e_1_2_10_9_1","volume-title":"PubChem Compound Summary for CID 124123797, Cedirogant","author":"National Center for Biotechnology Information"},{"issue":"1","key":"e_1_2_10_10_1","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13682","article-title":"Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis","volume":"17","author":"Mohamed MF","year":"2023","journal-title":"Clin Transl Sci"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1377"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1998.tb04806.x"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2004.11.112"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2009.21"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60125-8"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T01:39:54Z","timestamp":1720057194000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1002\/cpdd.1386"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1386","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]},"assertion":[{"value":"2023-11-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}